Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04947189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

Study acronym: 4CAST
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 15, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 2024 to Jul 2026
    • Study completion date: Dec 2024 to Dec 2027
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jul 2023 to Jul 2024
    • Start date changed from estimate of Nov 1, 2021 to Nov 1, 2022
    • Study sites: 0 to 1
    v3
  3. Start date: Jul 2021 to Nov 1, 2021v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
Trial Details
NCT Number NCT04947189
Lead Sponsor St Vincent's Hospital, Sydney
Conditions
(from sponsor)		 Triple Negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 65 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov